Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

68,794

Employees68,794

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

68,794

Employees68,794

NVO Key Statistics

Market cap

194.60B

Market cap194.60B

Price-Earnings ratio

10.74

Price-Earnings ratio10.74

Dividend yield

2.80%

Dividend yield2.80%

Average volume

9.29M

Average volume9.29M

High today

$43.61

High today$43.61

Low today

$42.72

Low today$42.72

Open price

$43.21

Open price$43.21

Volume

10.97M

Volume10.97M

52 Week high

$64.16

52 Week high$64.16

52 Week low

$35.12

52 Week low$35.12

NVO News

Nasdaq 3h

Could This New Opportunity Be Worth Billions for Novo Nordisk?

Key Points A recent clinical trial win could help Novo Nordisk expand its GLP-1 addressable market. The company is looking to bounce back after multiple setba...

Simply Wall St 8h

Is Novo Nordisk (CPSE:NOVO B) Cheap On New Childhood Obesity Trial Data? - simplywall.st

...

TipRanks 11h

Novo Nordisk Stock Falls After Morgan Stanley’s Sell Call on Market Share Loss to Eli Lilly, Patent Cliff

Novo Nordisk shares (NVO) fell by 2% to about $43 early Friday after Morgan Stanley analyst Thibault Boutherin downgraded the Danish pharma giant from Hold to S...

More NVO News

TipRanks 12h

Novo Nordisk downgraded to Underweight from Equal Weight at Morgan Stanley

Morgan Stanley downgraded Novo Nordisk (NVO) to Underweight from Equal Weight with an unchanged price target of $40. The firm cites concerns over the company’s...

Nasdaq 1d

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

Key Points AbbVie is successfully transitioning its revenue base toward newer immunology drugs to offset the loss of patent protection for Humira. Novo Nordis...

TipRanks 1d

Novo Nordisk’s Heart Failure Trial Setback: What NVO Investors Should Watch Next

Novo Nordisk (NVO) announced an update on their ongoing clinical study. The study “Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patient...

TipRanks 1d

Novo Nordisk’s CagriSema Trial Targets Painful Diabetic Nerve Damage

Novo Nordisk (NVO) announced an update on their ongoing clinical study. The study, officially titled “Efficacy and Safety of co Administered Cagrilintide and S...

Nasdaq 1d

Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.

Key Points Viking Therapeutics is studying its weight-loss drug candidate in phase 3 trials. Today Eli Lilly and Novo Nordisk dominate the market, but high de...

TipRanks 2d

Novo Nordisk Advances Oral Semaglutide Trial in Obesity: What Investors Should Watch

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Novo Nordisk’s new Phase 3 trial, “Efficacy and Safety of Once Daily Oral Semaglutide i...

TipRanks 2d

Novo Nordisk Advances DKK 15 Billion Share Buyback, Holding 1% of Capital in Treasury Stock

An announcement from Novo Nordisk ( (NVO) ) is now available. Novo Nordisk has continued executing its previously announced share repurchase programme, which f...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.